24-Mar-2026 8:20 AM CST - Benzinga Eli Lilly to phase out select insulin products across Europe by 2027 Eli Lilly and Co. LLY is phasing out select insulin products across parts of Europe for commercial reasons, with regulators emphasizing that the move is not linked to safety or quality concerns. The withdrawals,
20-Mar-2026 4:00 PM CST - Yahoo Finance Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial Eli Lilly and Company (NYSE:LLY) is one of the best long term stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) announced on March 16 positive topline results from the Phase 3 ADorable-1 trial that was evaluating the safety and efficacy of EBGLYSS in pediatric patients with moderate-to-severe atopic dermatitis.
19-Mar-2026 11:16 PM CST - Yahoo Finance RBC Capital Sees Eli Lilly's (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results Eli Lilly and Company (NYSE:LLY) is included among the 15 Dividend Stocks to Buy for Steady Income. On March 19, RBC Capital said the overall tolerability and A1C reductions for Eli Lilly and Company (NYSE:LLY)'s retatrutide in the TRANSCEND-T2D-1 study came in worse than Mounjaro for type 2 diabetes patients.
19-Mar-2026 12:36 PM CST - Yahoo Finance Canada Eli Lilly's next-generation obesity drug delivers strong results in late-stage trial Eli Lilly and Co (NYSE:LLY) has reported positive results from its late-stage trial of retatrutide, a next-generation obesity drug, demonstrating significant reductions in blood sugar levels and body weight.
19-Mar-2026 10:37 AM CST - Benzinga Eli Lilly says experimental diabetes drug shows weight loss of 17% Eli Lilly and Co LLY shares are down on Thursday. The company released news regarding its investigational drug, retatrutide, which has shown promising results in clinical trials. Eli Lilly Retatrutide Shows Strong A1C Reduction And Weight Loss Retatrutide is an investigational once-weekly triple hormone receptor agonist that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP),
24-Mar-2026 8:20 AM CST - Benzinga Eli Lilly to phase out select insulin products across Europe by 2027 Eli Lilly and Co. LLY is phasing out select insulin products across parts of Europe for commercial reasons, with regulators emphasizing that the move is not linked to safety or quality concerns. The withdrawals,
20-Mar-2026 4:00 PM CST - Yahoo Finance Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial Eli Lilly and Company (NYSE:LLY) is one of the best long term stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) announced on March 16 positive topline results from the Phase 3 ADorable-1 trial that was evaluating the safety and efficacy of EBGLYSS in pediatric patients with moderate-to-severe atopic dermatitis.
19-Mar-2026 11:16 PM CST - Yahoo Finance RBC Capital Sees Eli Lilly's (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results Eli Lilly and Company (NYSE:LLY) is included among the 15 Dividend Stocks to Buy for Steady Income. On March 19, RBC Capital said the overall tolerability and A1C reductions for Eli Lilly and Company (NYSE:LLY)'s retatrutide in the TRANSCEND-T2D-1 study came in worse than Mounjaro for type 2 diabetes patients.
19-Mar-2026 12:36 PM CST - Yahoo Finance Canada Eli Lilly's next-generation obesity drug delivers strong results in late-stage trial Eli Lilly and Co (NYSE:LLY) has reported positive results from its late-stage trial of retatrutide, a next-generation obesity drug, demonstrating significant reductions in blood sugar levels and body weight.
19-Mar-2026 10:37 AM CST - Benzinga Eli Lilly says experimental diabetes drug shows weight loss of 17% Eli Lilly and Co LLY shares are down on Thursday. The company released news regarding its investigational drug, retatrutide, which has shown promising results in clinical trials. Eli Lilly Retatrutide Shows Strong A1C Reduction And Weight Loss Retatrutide is an investigational once-weekly triple hormone receptor agonist that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP),
